Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 2/20 | 0.34 |
| ▸ | NOS2 | P35228 | 2/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3150690 | 0.87 | LOXL2 (0.33) | LOXL2 | |
| SCHEMBL1767952 | 0.87 | HRH4 (0.41) | CYP1A2POLBHRH4NOS3NOS2 | |
| Dimethylamine SCHEMBL9053689 | 0.80 | HRH4 (0.45) | CYP1A2POLBHRH4NOS3NOS2 | |
| SCHEMBL792959 | 0.76 | — | — | |
| SCHEMBL8153056 | 0.76 | — | — | |
| SCHEMBL20348521 | 0.74 | LOXL2 (0.37) | NOS3NOS2LOXL2NOS1 | |
| SCHEMBL805489 | 0.73 | — | — | |
| SCHEMBL17226870 | 0.73 | — | — | |
| SCHEMBL20801088 | 0.73 | NOS3 (0.37) | CYP1A2POLBHRH4NOS3NOS2 | |
| SCHEMBL25986789 | 0.73 | HRH4 (0.34) | CYP1A2POLBHRH4AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180186755-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2018-07-05 | — | — | US | disclosed |
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | NOVARTIS AG (CH) | 2008-06-05 | — | — | US | disclosed |
| CN-101103008-A | Macrocyclic compounds useful as bace inhibitors | NOVARTIS AG (CH) | 2008-01-09 | — | — | CN | disclosed |
| EP-1851208-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006074950-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186755-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | CYP1A2 387/4885POLB 1012/4885HRH4 3482/4885 |
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | BACE1, BACE2, APP | CYP1A2 2245/4885POLB 356/4885HRH4 2854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.